Artykuły w czasopismach na temat „Mutation BRAFV600E”
Utwórz poprawne odniesienie w stylach APA, MLA, Chicago, Harvard i wielu innych
Sprawdź 50 najlepszych artykułów w czasopismach naukowych na temat „Mutation BRAFV600E”.
Przycisk „Dodaj do bibliografii” jest dostępny obok każdej pracy w bibliografii. Użyj go – a my automatycznie utworzymy odniesienie bibliograficzne do wybranej pracy w stylu cytowania, którego potrzebujesz: APA, MLA, Harvard, Chicago, Vancouver itp.
Możesz również pobrać pełny tekst publikacji naukowej w formacie „.pdf” i przeczytać adnotację do pracy online, jeśli odpowiednie parametry są dostępne w metadanych.
Przeglądaj artykuły w czasopismach z różnych dziedzin i twórz odpowiednie bibliografie.
Lee, Min Hee, Seong Eun Lee, Dong Wook Kim, Min Jeong Ryu, Sung Jin Kim, Sung Joong Kim, Yong Kyoung Kim i in. "Mitochondrial Localization and Regulation of BRAFV600E in Thyroid Cancer: A Clinically Used RAF Inhibitor Is Unable to Block the Mitochondrial Activities of BRAFV600E". Journal of Clinical Endocrinology & Metabolism 96, nr 1 (1.01.2011): E19—E30. http://dx.doi.org/10.1210/jc.2010-1071.
Pełny tekst źródłaSahm, Felix, David Capper, Matthias Preusser, Jochen Meyer, Albrecht Stenzinger, Felix Lasitschka, Anna-Sophie Berghoff i in. "BRAFV600E mutant protein is expressed in cells of variable maturation in Langerhans cell histiocytosis". Blood 120, nr 12 (20.09.2012): e28-e34. http://dx.doi.org/10.1182/blood-2012-06-429597.
Pełny tekst źródłaChakraborty, Dhritiman, Sunil Shakya, Sanjana Ballal, Shipra Agarwal i Chandrasekhar Bal. "BRAFV600E and TERT promoter mutations in paediatric and young adult papillary thyroid cancer and clinicopathological correlation". Journal of Pediatric Endocrinology and Metabolism 33, nr 11 (26.11.2020): 1465–74. http://dx.doi.org/10.1515/jpem-2020-0174.
Pełny tekst źródłaDiamond, Eli L., Benjamin Durham, Ahmet Dogan, Mariko Yabe, Kseniya Petrova-Drus, Raajit K. Rampal, Raajit K. Rampal i in. "Phase 2 Trial of Single-Agent Cobimetinib for Adults with Histiocytic Neoplasms". Blood 142, Supplement 1 (28.11.2023): 1812. http://dx.doi.org/10.1182/blood-2023-187508.
Pełny tekst źródłaSong, Eyun, Meihua Jin, Ahreum Jang, Min Ji Jeon, Dong Eun Song, Hye Jin Yoo, Won Bae Kim, Young Kee Shong i Won Gu Kim. "Mutation in Genes Encoding Key Functional Groups Additively Increase Mortality in Patients with BRAFV600E-Mutant Advanced Papillary Thyroid Carcinoma". Cancers 13, nr 22 (22.11.2021): 5846. http://dx.doi.org/10.3390/cancers13225846.
Pełny tekst źródłaKaneko, Masanao, Mitsuko Nakashima, Kiichi Sugiura, Natsuki Ishida, Satoshi Tamura, Shinya Tani, Mihoko Yamade i in. "Both MLH1 deficiency and BRAFV600E mutation are a unique characteristic of colorectal medullary carcinoma: An observational study". Medicine 102, nr 38 (22.09.2023): e35022. http://dx.doi.org/10.1097/md.0000000000035022.
Pełny tekst źródłaAscierto, Paolo A., David Minor, Antoni Ribas, Celeste Lebbe, Anne O'Hagan, Niki Arya, Mary Guckert i in. "Phase II Trial (BREAK-2) of the BRAF Inhibitor Dabrafenib (GSK2118436) in Patients With Metastatic Melanoma". Journal of Clinical Oncology 31, nr 26 (10.09.2013): 3205–11. http://dx.doi.org/10.1200/jco.2013.49.8691.
Pełny tekst źródłaMorris, Van K., Kanwal Pratap Singh Raghav, Arvind Dasari, Michael J. Overman, Bryan K. Kee, Benny Johnson, Christine Megerdichian Parseghian i in. "Utility of circulating tumor DNA in the clinical management of patients with BRAFV600E metastatic colorectal cancer." Journal of Clinical Oncology 39, nr 3_suppl (20.01.2021): 119. http://dx.doi.org/10.1200/jco.2021.39.3_suppl.119.
Pełny tekst źródłaSmyrk, Thomas C., David Tougeron, Stephen N. Thibodeau, Shalini Singh, Andrea Muranyi, Kandavel Shanmugam, Thomas M. Grogan, Steven R. Alberts, Qian Shi i Frank A. Sinicrope. "Detection of the BRAFV600E protein in human colon carcinomas by a mutation-specific antibody." Journal of Clinical Oncology 31, nr 15_suppl (20.05.2013): 3576. http://dx.doi.org/10.1200/jco.2013.31.15_suppl.3576.
Pełny tekst źródłaChoi, Yun-Suk, Seong-Woon Choi i Jin-Wook Yi. "Prospective Analysis of TERT Promoter Mutations in Papillary Thyroid Carcinoma at a Single Institution". Journal of Clinical Medicine 10, nr 10 (18.05.2021): 2179. http://dx.doi.org/10.3390/jcm10102179.
Pełny tekst źródłaSong, Young Shin, Seong-Keun Yoo, Hwan Hee Kim, Gyeongseo Jung, Ah-Reum Oh, Ji-Young Cha, Su-jin Kim i in. "Interaction of BRAF-induced ETS factors with mutant TERT promoter in papillary thyroid cancer". Endocrine-Related Cancer 26, nr 6 (czerwiec 2019): 629–41. http://dx.doi.org/10.1530/erc-17-0562.
Pełny tekst źródłaWang, Liye, Qianyi Lu, Kuikui Jiang, Ruoxi Hong, Shusen Wang i Fei Xu. "BRAF V600E Mutation in Triple-Negative Breast Cancer: A Case Report and Literature Review". Oncology Research and Treatment 45, nr 1-2 (24.11.2021): 54–61. http://dx.doi.org/10.1159/000520453.
Pełny tekst źródłaGąsior-Perczak, Danuta, Artur Kowalik, Agnieszka Walczyk, Monika Siołek, Krzysztof Gruszczyński, Iwona Pałyga, Estera Mikina i in. "Coexisting Germline CHEK2 and Somatic BRAFV600E Mutations in Papillary Thyroid Cancer and Their Association with Clinicopathological Features and Disease Course". Cancers 11, nr 11 (7.11.2019): 1744. http://dx.doi.org/10.3390/cancers11111744.
Pełny tekst źródłaNikiforovich, P. A., A. P. Polyakov, I. V. Sleptsov, N. S. Boyko, Yu A. Gronskaya, N. I. Timofeeva i R. A. Chernikov. "Targeted therapy of anaplastic thyroid cancer". Head and Neck Tumors (HNT) 12, nr 4 (8.03.2023): 33–38. http://dx.doi.org/10.17650/2222-1468-2022-12-4-33-38.
Pełny tekst źródłaEmile, Jean-François, Eli L. Diamond, Zofia Hélias-Rodzewicz, Fleur Cohen-Aubart, Frédéric Charlotte, David M. Hyman, Eunhee Kim i in. "Recurrent RAS and PIK3CA mutations in Erdheim-Chester disease". Blood 124, nr 19 (6.11.2014): 3016–19. http://dx.doi.org/10.1182/blood-2014-04-570937.
Pełny tekst źródłaJin, Lei, Liang Zhou, Jian-Biao Wang, Li Tao, Xiao-Xiao Lu, Na Yan, Qian-Ming Chen, Li-Ping Cao i Lei Xie. "Whether Detection of Gene Mutations Could Identify Low- or High-Risk Papillary Thyroid Microcarcinoma? Data from 393 Cases Using the Next-Generation Sequencing". International Journal of Endocrinology 2024 (16.01.2024): 1–12. http://dx.doi.org/10.1155/2024/2470721.
Pełny tekst źródłaSui, Jane Sze Yin, Marc Ladanyi, Charles M. Rudin, Alexander E. Drilon, Gregory J. Riely, Mark G. Kris i Michael Offin. "Clinicopathologic and mutational landscape of BRAFV600E-mutant non–small cell lung carcinoma." Journal of Clinical Oncology 40, nr 16_suppl (1.06.2022): 9084. http://dx.doi.org/10.1200/jco.2022.40.16_suppl.9084.
Pełny tekst źródłaSui, Jane Sze Yin, Marc Ladanyi, Charles M. Rudin, Alexander E. Drilon, Gregory J. Riely, Mark G. Kris i Michael Offin. "Clinicopathologic and mutational landscape of BRAFV600E-mutant non–small cell lung carcinoma." Journal of Clinical Oncology 40, nr 16_suppl (1.06.2022): 9084. http://dx.doi.org/10.1200/jco.2022.40.16_suppl.9084.
Pełny tekst źródłaLiu, Shiyang, Bo Jiao, Shuyu Li, Lu Zhao, Weihong Zheng, Kun Wang, Jing Xu i in. "Oestrogen receptor alpha in papillary thyroid carcinoma: association with clinical features and BRAFV600E mutation". Japanese Journal of Clinical Oncology 51, nr 7 (24.04.2021): 1051–58. http://dx.doi.org/10.1093/jjco/hyab058.
Pełny tekst źródłaJouenne, Fanélie, Sylvie Chevret, Emmanuelle Bugnet, Emmanuelle Clappier, Gwenaël Lorillon, Véronique Meignin, Aurélie Sadoux i in. "Genetic landscape of adult Langerhans cell histiocytosis with lung involvement". European Respiratory Journal 55, nr 2 (5.12.2019): 1901190. http://dx.doi.org/10.1183/13993003.01190-2019.
Pełny tekst źródłaDong, Si-Yang, Jie Chen, Er-Jie Xia, Ri-Xu Lin, Hai-Yan Du, Ou-Chen Wang, Xiao-Hua Zhang i Ru-Tian Hao. "Clinical Analysis of BRAFV600E Mutation and Its Correlation With Sonographic Image Characteristics in Papillary Thyroid Carcinoma in Chinese Coastal Areas". American Surgeon 86, nr 5 (maj 2020): 450–57. http://dx.doi.org/10.1177/0003134820919734.
Pełny tekst źródłaElisei, Rossella, Clara Ugolini, David Viola, Cristiana Lupi, Agnese Biagini, Riccardo Giannini, Cristina Romei, Paolo Miccoli, Aldo Pinchera i Fulvio Basolo. "BRAFV600E Mutation and Outcome of Patients with Papillary Thyroid Carcinoma: A 15-Year Median Follow-Up Study". Journal of Clinical Endocrinology & Metabolism 93, nr 10 (1.10.2008): 3943–49. http://dx.doi.org/10.1210/jc.2008-0607.
Pełny tekst źródłaYamazaki, Kentaro, Takayuki Yoshino, Katsuya Tsuchihara, Eiji Shinozaki, Kei Muro, Tomohiro Nishina, Kensei Yamaguchi i in. "Clinical impact of expanded BRAF mutational status on the outcome for metastatic colorectal cancer patients with anti-EGFR antibody: An analysis of the BREAC trial (Biomarker Research for Anti-EGFR Monoclonal Antibodies by Comprehensive Cancer Genomics)." Journal of Clinical Oncology 33, nr 3_suppl (20.01.2015): 573. http://dx.doi.org/10.1200/jco.2015.33.3_suppl.573.
Pełny tekst źródłaSoria, Xavier, Felip Vilardell, Óscar Maiques, Carla Barceló, Pol Sisó, Inés de la Rosa, Ana Velasco i in. "BRAFV600E Mutant Allele Frequency (MAF) Influences Melanoma Clinicopathologic Characteristics". Cancers 13, nr 20 (11.10.2021): 5073. http://dx.doi.org/10.3390/cancers13205073.
Pełny tekst źródłaAttia, Abdallah S., Mohammad Hussein, Peter P. Issa, Ahmad Elnahla, Ashraf Farhoud, Brandon M. Magazine, Mohanad R. Youssef i in. "Association of BRAFV600E Mutation with the Aggressive Behavior of Papillary Thyroid Microcarcinoma: A Meta-Analysis of 33 Studies". International Journal of Molecular Sciences 23, nr 24 (9.12.2022): 15626. http://dx.doi.org/10.3390/ijms232415626.
Pełny tekst źródłaHong, Xiaoquan, Juxiang Li, Shaoyin Duan i Youkuang You. "Retrospective study of BRAFV600E mutation and CT features of papillary thyroid carcinoma". PeerJ 12 (24.01.2024): e16810. http://dx.doi.org/10.7717/peerj.16810.
Pełny tekst źródłaJING, Fan-jing, Jun LIANG, Zhi-yong LIANG, Chao MENG, Wen LONG, Xiao-yi LI i Yan-song LIN. "BRAFV600E mutation is not a positive predictor for distant metastasis in sporadic papillary thyroid carcinoma". Chinese Medical Journal 126, nr 16 (30.08.2013): 3013–18. http://dx.doi.org/10.3760/cma.j.issn.0366-6999.20122032.
Pełny tekst źródłaLi, Fei, Guangqi Chen, Chunjun Sheng, Aaron M. Gusdon, Yueye Huang, Zhongwei Lv, Huixiong Xu, Mingzhao Xing i Shen Qu. "BRAFV600E mutation in papillary thyroid microcarcinoma: a meta-analysis". Endocrine-Related Cancer 22, nr 2 (15.01.2015): 159–68. http://dx.doi.org/10.1530/erc-14-0531.
Pełny tekst źródłaOtieno, Steve Biko, Syed Nasir, Alva Weir i Robert Johnson. "Rapid Response in a Patient with Relapsed/Refractory Multiple Myeloma Treated with BRAF/MEK Inhibitors". Case Reports in Hematology 2020 (11.12.2020): 1–4. http://dx.doi.org/10.1155/2020/8821415.
Pełny tekst źródłaKim, Suk Kyeong, Tae Sook Hwang, Young Bum Yoo, Hye Seung Han, Dong-Lim Kim, Kee-Ho Song, So Duk Lim, Wan Seop Kim i Nam Sun Paik. "Surgical Results of Thyroid Nodules according to a Management Guideline Based on the BRAFV600E Mutation Status". Journal of Clinical Endocrinology & Metabolism 96, nr 3 (1.03.2011): 658–64. http://dx.doi.org/10.1210/jc.2010-1082.
Pełny tekst źródłaWei, Xiaojing, Xiaodong Wang, Jie Xiong, Chen Li, Yixuan Liao, Yongjun Zhu i Jingxin Mao. "Risk and Prognostic Factors for BRAFV600E Mutations in Papillary Thyroid Carcinoma". BioMed Research International 2022 (18.05.2022): 1–13. http://dx.doi.org/10.1155/2022/9959649.
Pełny tekst źródłaColle, Raphael, Sara Lonardi, Marine Cachanado, Michael J. Overman, Elena Elez, Marwan Fakih, Francesca Corti i in. "Impact of Lynch syndrome, BRAFV600E, and RAS mutations on outcomes in MSI/dMMR metastatic colorectal cancer (mCRC) treated with immune checkpoint inhibitors (ICI): Analysis of combined international cohorts." Journal of Clinical Oncology 41, nr 4_suppl (1.02.2023): 171. http://dx.doi.org/10.1200/jco.2023.41.4_suppl.171.
Pełny tekst źródłaNechifor-Boilă, Adela, Ancuţa Zahan, Claudia Bănescu, Valeriu Moldovan, Doina Piciu, Septimiu Voidăzan i Angela Borda. "Impact of BRAFV600E Mutation on Event-Free Survival in Patients with Papillary Thyroid Carcinoma: A Retrospective Study in a Romanian Population". Cancers 15, nr 16 (11.08.2023): 4053. http://dx.doi.org/10.3390/cancers15164053.
Pełny tekst źródłaHyman, David M., Eli Diamond, Cecile Rose Vibat, Latifa Hassaine, Jason Poole, Minal Patel, Veronica Holley i in. "Prospective Blinded Study of BRAFV600E Mutation Detection in Cell-Free DNA of Patients with Systemic Histiocytic Disorders". Blood 124, nr 21 (6.12.2014): 1833. http://dx.doi.org/10.1182/blood.v124.21.1833.1833.
Pełny tekst źródłaVignali, Paola, Elisabetta Macerola, Anello Marcello Poma, Rebecca Sparavelli i Fulvio Basolo. "Indeterminate Thyroid Nodules: From Cytology to Molecular Testing". Diagnostics 13, nr 18 (20.09.2023): 3008. http://dx.doi.org/10.3390/diagnostics13183008.
Pełny tekst źródłaZhu, Guoquan, Yuying Deng, Liqin Pan, Wei Ouyang, Huijuan Feng, Juqing Wu, Pan Chen, Jing Wang, Yanying Chen i Jiaxin Luo. "Clinical significance of the BRAFV600E mutation in PTC and its effect on radioiodine therapy". Endocrine Connections 8, nr 6 (czerwiec 2019): 754–63. http://dx.doi.org/10.1530/ec-19-0045.
Pełny tekst źródłaM S, Bhuvitha, i Krishna G. "BRAFV600E Mutation in Papillary Carcinoma Thyroid". Annals of Pathology and Laboratory Medicine 9, nr 6 (9.07.2022): A102–108. http://dx.doi.org/10.21276/apalm.3167.
Pełny tekst źródłaHéritier, Sébastien, Jean-François Emile, Mohamed-Aziz Barkaoui, Caroline Thomas, Sylvie Fraitag, Sabah Boudjemaa, Florence Renaud i in. "BRAF Mutation Correlates With High-Risk Langerhans Cell Histiocytosis and Increased Resistance to First-Line Therapy". Journal of Clinical Oncology 34, nr 25 (1.09.2016): 3023–30. http://dx.doi.org/10.1200/jco.2015.65.9508.
Pełny tekst źródłaPamedytyte, Daina, Vaida Simanaviciene, Dalia Dauksiene, Enrika Leipute, Aurelija Zvirbliene, Valdas Sarauskas, Albertas Dauksa, Rasa Verkauskiene i Birute Zilaitiene. "Association of microRNA Expression and BRAFV600E Mutation with Recurrence of Thyroid Cancer". Biomolecules 10, nr 4 (17.04.2020): 625. http://dx.doi.org/10.3390/biom10040625.
Pełny tekst źródłaHardee, Steven, Manju L. Prasad, Pei Hui, Catherine A. Dinauer i Raffaella A. Morotti. "Pathologic Characteristics, Natural History, and Prognostic Implications of BRAFV600E Mutation in Pediatric Papillary Thyroid Carcinoma". Pediatric and Developmental Pathology 20, nr 3 (8.02.2017): 206–12. http://dx.doi.org/10.1177/1093526616689628.
Pełny tekst źródłaGadde, Samata. "Lack of the BRAFV600E Mutation in Oral Squamous Cell Carcinoma". Journal of Medical Science And clinical Research 04, nr 12 (25.12.2016): 14912–16. http://dx.doi.org/10.18535/jmscr/v4i12.99.
Pełny tekst źródłaYoon, Jiyoung, Eunjung Lee, Ja Seung Koo, Jung Hyun Yoon, Kee-Hyun Nam, Jandee Lee, Young Suk Jo, Hee Jung Moon, Vivian Youngjean Park i Jin Young Kwak. "Artificial intelligence to predict the BRAFV600E mutation in patients with thyroid cancer". PLOS ONE 15, nr 11 (25.11.2020): e0242806. http://dx.doi.org/10.1371/journal.pone.0242806.
Pełny tekst źródłaMaaitah, Alaa Al, Moaath Alsmady, Shatha Dmour, Dana Alsmady, Ahmad Al Alwan, Mira Younis, Mohammad Al Shhab i in. "The Prevalence and Prognostic Value of BRAFV600E Mutation in Papillary Thyroid Cancer". International Journal of Human and Health Sciences (IJHHS) 3, nr 4 (1.09.2019): 223. http://dx.doi.org/10.31344/ijhhs.v3i4.106.
Pełny tekst źródłaAcosta-Medina, Aldo A., Jithma P. Abeykoon, N. Nora Bennani, Caroline Davidge-Pitts, Matthew J. Koster, Aishwarya Ravindran, Karen Rech i in. "BRAFV600E frequency and impact on outcomes in adults with langerhans cell histiocytosis." Journal of Clinical Oncology 39, nr 15_suppl (20.05.2021): 7050. http://dx.doi.org/10.1200/jco.2021.39.15_suppl.7050.
Pełny tekst źródłaSalem, Mohamed E., Scott Kopetz, Sherif Mohamed El-Refai, Josep Tabernero, Frank A. Sinicrope, Jeanne Tie, Thomas J. George i in. "Comparative analysis of microsatellite instability-high (MSI-H) BRAF V600E-mutated versus MSI-H BRAFwild type colorectal cancers (CRC), including tumor microenvironment (TME), associated genomic alterations, and immunometabolomic biomarkers." Journal of Clinical Oncology 40, nr 16_suppl (1.06.2022): 3066. http://dx.doi.org/10.1200/jco.2022.40.16_suppl.3066.
Pełny tekst źródłaSalem, Mohamed E., Scott Kopetz, Sherif Mohamed El-Refai, Josep Tabernero, Frank A. Sinicrope, Jeanne Tie, Thomas J. George i in. "Comparative analysis of microsatellite instability-high (MSI-H) BRAF V600E-mutated versus MSI-H BRAFwild type colorectal cancers (CRC), including tumor microenvironment (TME), associated genomic alterations, and immunometabolomic biomarkers." Journal of Clinical Oncology 40, nr 16_suppl (1.06.2022): 3066. http://dx.doi.org/10.1200/jco.2022.40.16_suppl.3066.
Pełny tekst źródłaBaldari, Silvia, Giuliana Di Rocco, Marie C. Heffern, Timothy A. Su, Christopher J. Chang i Gabriele Toietta. "Effects of Copper Chelation on BRAFV600E Positive Colon Carcinoma Cells". Cancers 11, nr 5 (12.05.2019): 659. http://dx.doi.org/10.3390/cancers11050659.
Pełny tekst źródłaWieczorek-Szukala, Katarzyna, Janusz Kopczynski, Aldona Kowalska i Andrzej Lewinski. "Snail-1 Overexpression Correlates with Metastatic Phenotype in BRAFV600E Positive Papillary Thyroid Carcinoma". Journal of Clinical Medicine 9, nr 9 (21.08.2020): 2701. http://dx.doi.org/10.3390/jcm9092701.
Pełny tekst źródłaChoden, Sonam, Somboon Keelawat, Chan Kwon Jung i Andrey Bychkov. "VE1 Immunohistochemistry Improves the Limit of Genotyping for Detecting BRAFV600E Mutation in Papillary Thyroid Cancer". Cancers 12, nr 3 (5.03.2020): 596. http://dx.doi.org/10.3390/cancers12030596.
Pełny tekst źródłaLee, Hey Min, Stefania Napolitano, Van K. Morris, Kunal Rai, John Paul Y. C. Shen, Jennifer S. Davis, Dipen M. Maru i in. "Epigenetic regulation of the Wnt-signaling pathway in CIMP-H BRAFV600E mCRC." Journal of Clinical Oncology 39, nr 3_suppl (20.01.2021): 110. http://dx.doi.org/10.1200/jco.2021.39.3_suppl.110.
Pełny tekst źródła